Researchory

Nanoparticle-Enabled Targeted Drug Delivery: Revolutionizing Pharmacotherapy

Review Paper
Sarah Rodrigues
Cambridge International School

Abstract:
Targeted delivery systems using nanoparticles represent a quantum leap in pharmacotherapy for the delivery of therapeutic drugs at the site of disease with enhanced efficacy and lesser side effects. This paper combines recent advances (2018–2025) in nanoparticle mediated drug delivery with a focus on the effect on chronic diseases like cancer, cardiovascular diseases and neurologic diseases. From an examination of multiple peer-reviewed journal documents appeared within the recent past in nanotechnology and pharmacology we describe how the nanoparticle carriers increase bioavailability and stability and provide controlled release of drugs. Findings indicate enhanced therapeutic indices and patient benefit but difficulties in scaling up and long-term safety. The novelty of this overview lies in offering a comprehensive view on the integration of design principles, target strategies, and clinical considerations specifically for chronic diseases. Notably, these inferences provide hints toward the translational future of nanoparticle delivery systems towards their future in personalized medicine and creation of safer and effective therapeutics.

Keywords: nanoparticle, targeted drug delivery, pharmacotherapy, nanocarriers, biocompatibility

Abbreviations Used:

- **FDA**: Food and Drug Administration
- **EPR**: Enhanced Permeability and Retention
- **OECD**: Organisation for Economic Co-operation and Development
- **MRI**: Magnetic Resonance Imaging
- **PRISMA**: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Introduction:

Conventional pharmacotherapy is marked by deficiencies of low drug solubility, systemic side effects and lack of specificity, which limit therapeutic efficacy. This is particularly critical given the global burden of chronic diseases with cancer causing almost 10 million deaths in the world in 2020 and cardiovascular diseases for roughly 17.9 million deaths annually. Additionally, ill-health, disability and premature mortality from neurological disorders was said to have increased by 18% since 1990, illustrating the need for proper healthcare interventions like drug delivery using nanoparticles, which assist the patient better as they can traverse biological barriers and offer better stability to drugs.

Nanoparticle drug delivery provides a different model by using nanosized carriers like liposomes, polymeric nanoparticles, dendrimers and inorganic nanoparticles for more efficient drug targeting and reduced off-target activity. Carriers employ physicochemical properties such as size, charge and ligand functionalization to traverse biological barriers and deliver drugs in a controlled fashion. The clinical relevance of nanoparticles is exemplified

by Doxil, the first FDA-approved nano-formulated drug in 1995, used to treat Kaposi's sarcoma in patients with HIV, demonstrating that nanomedicine can translate into effective therapies.

Literature Review

Nanoparticle Design and Types:

The nanoparticles are highly diverse in composition and purpose. Biocompatibility and elasticity of the lipid-based carriers are inherent characteristics of their functions. Polymeric nanoparticles regulate the release of the drug by controlled release mechanisms based on degradation-kinetics. Inorganic nanoparticles are used in imaging-guided therapy and dual theragnostic application (silica, gold). Specificity is enhanced by surface modification with targeting ligands like peptides, antibodies. Contemporary research offers nanoparticulate systems particularly tailored for targeting delivery to the cancer cell and penetration of the blood-brain barrier in the event of neurotherapeutics.

These ideas have been brought into clinically effective therapeutics, providing concrete examples to demonstrate how nanoparticle-mediated targeted delivery of drugs can enhance the outcomes for the patient. Example Onivyde® and Vyxeos®. ONIVYDE is a liposomal formulation of irinotecan for the treatment of metastatic pancreatic adenocarcinoma and Vyxeos is a liposomal formulation of both cytarabine/daunorubicin for the treatment of therapy-related acute myeloid leukaemia.

This table shows the main types of nanoparticles and their key advantages and limitations:

Nanoparticle Type	Advantages	Limitations
Lipid-based nanoparticles	Biocompatible, elastic, can encapsulate hydrophilic and hydrophobic drugs, prolonged circulation	Potential instability, limited drug loading for some molecules
Polymeric nanoparticles	Controlled drug release via degradation-kinetics, adjustable properties	Potential toxicity of polymers, slower clinical translation
Inorganic nanoparticles (e.g., silica, gold)	Imaging-guided therapy, dual theranostic applications	Limited biodegradability, possible long-term accumulation
Surface-modified nanoparticles	Enhanced specificity via targeting ligands (peptides, antibodies), improved cellular uptake	Complexity in synthesis, minimal possibility of immunogenicity

Safety and Toxicity:

The nanoparticles possess realistic drug delivery advances based on their physical properties of systemic stability, solubility and site-specific targeting in the target organ. Nonetheless, their use poses new concerns of toxicity and safety to be met by stringent toxicological assessment prior to use on a human. The toxicity of nanoparticles for drug delivery beyond

the level of the normal monomers in the classical delivery matrices is mainly attributed to the particle size, which allow penetration of multiple biological barriers, even those of the brain and the cell compartment. While this method is useful for specific targeting, it is still associated with its risks.

Consequently the risk-benefit evaluation of the nanoparticulate formulations is to be carried on a case-to-case basis and not just the toxicological information of the bulk material alone. Special emphasis must therefore come in the identification of the toxicity of the non-drug loaded nanoparticles, particularly where the nanoparticles are non-degradable or slow-degrading, risk of build-up and the related risk of chronic inflammatory response.

Additionally, the use of standardized testing and protocols to nanomaterial toxicity are required for the determination of its safety. Guides such as the OECD protocols and nanotoxicity assays provide systematized forms for the determination of cytotoxicity, genotoxicity and inflammatory response to nanoparticles. OECD protocols are regulated guidelines that help evaluate the long term and short term safety of a patient based technology. For nanoparticle enabled targeted drug delivery it is used to assess its physiochemical properties, biodistribution and overall impact on a patient. It can also be used as evaluation to its environmental impact by its potential to cause build up.

Mechanisms:

Targeting strategies are of two types: active and passive. Passive targeting is facilitated by the enhanced permeability and retention (EPR) effect, wherein the nanoparticles are able to permeate preferentially through the tumour tissue due to the leaky vasculature and lack of lymphatic drainage of the tumour tissue. This functions best in solid tumours but does not function in heterogeneous tissues or organs with thin-lined endothelial barriers. Active targeting maximizes specificity by ligand conjugation (antibodies, peptides, or small molecules) on the surface of the nanoparticles, recognizing selective binding to receptors overexpressed on the target diseased cells. This optimizes not only cell uptake but also reduces off-target toxicity. Stimulus-responsive systems impart the additional level of precision by drug release based on local environmental stimulus such as acidosis, heat, or specific enzymatic activity, optimizing yet further therapeutic control and allowing combination or multi-modal therapies. Combining passive, active and stimulus-responsive mechanisms allows the development of multi-functional nanoparticles capable of sequential or targeted release in complex disease environments, further enhancing therapeutic precision. Other emerging strategies in the works include the exosome-mimetic nanoparticles that naturally circumvent the immune system and nanocarriers that directly modify the genes in making the treatment personalized.



Figure 1: Mechanisms of Nanoparticle-Mediated CSC Targeting

Clinical Implications:

Nanoparticle drug delivery has been successful in clinical trials and most notably in oncology and cardiovascular treatment. For example the depot delivery of doxorubicin chemotherapeutic in liposomes by the formulation Doxil. This treatment has widened the therapeutic window in cancer treatment by limiting the cardiotoxicity of the drug. Other novel systems for atherosclerotic plaques and neurodegenerative disease are under development, with encouraging early-phase clinical results. Development continues to take place, with multi-functional nanoparticles for dual imaging and treatment, dose individualization and minimization of systemic toxicity. While the future of nanoparticle drug delivery is promising, several challenges stand in the way of broad clinical application. Immune stimulation may lead to rapid clearance of nanoparticles from circulation and reduced therapeutic activity. Additionally, due to the fear of sustained distribution in organs such as the liver, spleen or kidney with potential long-term toxicity, it raises potential long-term health concerns. Lastly, scaling up bench-scale production to industrial-scale production remains challenging. The control of uniform particle size, surface properties and drug-loading efficiency are critical for safety and regulatory approval. Overcoming these challenges is crucial to ensure the benefits of nanoparticle-based therapies in everyday clinic applications.

Physicochemical properties:

Physicochemical variables like charge at the surface have effects on circulation time and cellular uptake so that nanoparticles with a positive charge are generally of greater uptake but potentially greater toxicity. Additionally, the use of nano-based drug delivery is mainly due to the difference in surface area from traditional drug delivery. Its higher surface area to volume ratio allows for more drug to be loaded and for the target of delivery to be highly specific. Low solubility drugs can be more easily and efficiently carried out for delivery with nanoparticles due to its surface area. Stability and chemical structure control biocompatibility with direct effects upon drug release profiles. This in turn, increases biodistribution affecting its permeability and retention effect. Furthermore, nanoparticles themselves have the natural, inherent propensity to aggregate that can shift biodistribution and lessen targeting efficacy. Chemical modification by deposition with polymers or ligands enhances targeting specificity and increases solubility. Generally, such variables are of greatest importance in customized nanoparticles to achieve both safety and efficiency.

Methodology:
A search of PubMed, Scopus and Web of Science for the following search terms: “nanoparticles,” “targeted drug delivery,” “liposomes,” “polymeric nanoparticles,” “nanocarriers,” and “nano-theranostics” has been utilized. Articles published in the English language in the year 2018 and 2025 were evaluated. Title and abstracts were screened for the importance of nanoparticle-based drug delivery for cancer, cardiovascular and neurodegenerative disease. Article shortlisting on the basis of mechanisms of drug delivery, clinical findings, toxicity and safety of the nanoparticle formulations were considered. Data of the studies were synthesized to consolidate the recent advances, mechanisms and clinical applications of nanoparticle-based therapeutics.

Abstracts and titles were initially put through screening by relevance. Full papers of studies eligible were then reviewed closely. I undertook PRISMA methodology so that maximum transparency of studies selection was achieved. I also traced the number of studies at every stage by the simplified PRISMA-style flow diagram (identification, screening, eligibility, inclusion).

Discussion:
Nanotechnology in drug delivery has significant benefits: increased solubilization of drugs, drug delivery targeting of less toxic drugs within the system and sustained release with enhanced pharmacokinetics. For example, poor water-soluble chemotherapeutics like paclitaxel and curcumin exhibit improved bioavailability following encapsulation in lipid or polymeric nanoparticles. In the same way, nanoparticulate carriers can preserve labile drugs from enzymatic degradation and improve circulation half-life, resulting in improved therapeutic effects. In addition, controlled release mechanisms enable steady-state levels of the drug within the target site with minimized peak-trough excursions and improved patient compliance. Clinical literature also consistently reports enhanced patient outcome and less side effect relative to traditional therapy. Several clinical trials of oncology, cardiovascular disease and neurodegenerative disease have shown to create improved efficacy and lower systemic toxicity with products based on nano-particulates, highlighting their translational potential.

Compared with other advanced drug delivery platforms, nanoparticles have certain advantages. Though hydrogels and microspheres have localized or controlled release they are generally unable to penetrate such potent biological barriers like the blood or brain barrier. One of the advances of recent years has been the application of lipid nanoparticles of mRNA vaccines (such as the COVID-19 vaccines) which have at the same time demonstrated their delivery efficiency and clinical relevance under practical conditions. This comparison brings nanoparticles into sharp focus as incredibly flexible platforms both for classical small-molecule therapeutics and forthcoming biologics.

Lastly, imaging-based and targeted delivery approaches to personalized therapy hold a new future. Theranostic applications of multifunctional nanoparticles with dual therapeutic and imaging capabilities hold one such future. For example, Gold or iron oxide nanoparticles allowing MRI imaging and drug targeting simultaneously and the response to treatment can even be monitored in real-time. Additional precision can be achieved through stimulus-responsive nanoparticles. These particles are made to release drugs when encountering stimuli such as pH, temperature or enzymes cues.

The disparity between preclinical lead information and clinical translation highlights the need for standardized evaluation protocols and enhanced knowledge about immune system interactions of nanoparticles. Efficient designing of nanoparticles, understanding pharmacokinetic in the human system and development of regulation-compliant manufacture processes are the pivots in bridging the gap. Scalability, regulation and safety profiles must be addressed in upcoming research in an effort to further accelerate clinical uptake. Long-term biodegradability, safety and potential nanotoxicity need to be further explored. For example, some studies show that inorganic nanoparticles have potential to accumulate in organs like the spleen or liver, further proving extensive in clinical studies must be performed in order to determine safety of it.

Future perspectives are likely to be shaped by some of the emerging trends. For example, AI-aided nanocarrier design holds the potential to accelerate the optimization of particle size, surface chemistry and targeting ligands. Personalized nanomedicine, with nanocarriers engineered at the patient's genomic or proteomic level, holds the potential to be truly patient-specific treatment. Organ-on-a-chip technologies hold the potential to allow preclinical screening of nanoparticle safety and efficacy under human-relevant microenvironment before translating into human studies, bridging the translational gap. Overall, the strategies envision a future where nanoparticle drug delivery isn't just more effective but safer, scalable and integrated holistically into precision medicine.

Results:

Survey of the chosen literature reports show promising developments in drug nanoparticle-based targeting of drugs against cancer, cardiovascular and neurodegenerative disease conditions. The key findings of which are listed in Table 1.

Referenced	Nanoparticle	Disease	Delivery Mechanism	Safety/Toxicity
[1]	Liposomes	Cancer	Passive targeting	Very low toxicity
[15]	Lipid-based	Cancer	Active targeting	Low toxicity in preclinical studies
[13]	Polymeric	Cancer	Passive targeting	Mild inflammatory response
[20]	Polymeric or lipid-based	Cardiovascular	Active targeting	No major effects reported
[21]	Nanoparticle-based carriers	Cardiovascular	Stimuli-responsive	Safety profile acceptable. Unknown long-term effects
[26]	Lipid-based	Neurodegenerative	Stimuli-responsive	Potential accumulation in nervous system. Unknown long-term effects
[27]	Polymeric	Neurodegenerative	Active targeting	Preclinical studies show low toxicity
[16]	Iron oxide	Cancer	Theragnostic	Potential to accumulate in liver and spleen.

Table 1: Key Findings

This indicates significant advancements in nanoparticle-based drug delivery across cancer, cardiovascular, and neurodegenerative diseases. Liposomal and lipid-based nanoparticles have demonstrated efficient passive and active targeting with minimal toxicity in preclinical and clinical studies, while polymeric nanoparticles offer controlled drug release with generally low inflammatory responses. Stimuli-responsive systems show promise for precise delivery in cardiovascular and neurodegenerative conditions, though potential long-term accumulation in organs such as the liver, spleen, and nervous system remains a consideration. Theranostic nanoparticles, including iron oxide formulations, provide dual imaging and therapeutic functionality, further highlighting the versatility and translational potential of nanoparticle-enabled therapies (see Table 1).

Final Conclusion:
Targeted drug delivery through nanoparticles is an innovative method of pharmacotherapy that has offered enhanced specificity, efficiency and safety of drugs. In this article, we summarize recent developments in nanomaterial design, delivery and target mechanisms and clinical translation application in diseases. Scalability and safety issues persist in spite of promises of precision and per-personalization through these technologies. Future research must exceed translational barriers and multi-modal combined therapy implementation.

Future research must address translational barriers and multi-modal combined therapy implementation. Looking forward, genomics nanotechnology convergence, nanocarrier design with AI and efficient regulations will eventually expedite translational applications in the clinic and broaden the spectrum of therapeutic applications of nanoparticle-based therapies. It will entail vigorous interdisciplinary interactions among clinicians, nano-scientists, drug discoverers and regulatory scientists so that therapies are both safe and effective and generally available

Positive findings include **i**mproved therapeutic indices, enhanced patient outcomes and successful clinical translation as seen with Doxil® and mRNA lipid nanoparticle vaccines. **Negative findings** include potential long-term accumulation in organs, scalability challenges in manufacturing and immune clearance that may reduce efficacy. These underscore the need for further preclinical and clinical evaluation and standardized safety protocols.

References:

1. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020). Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. *Frontiers in Molecular Biosciences*, *7*(193). https://doi.org/10.3389/fmolb.2020.00193
2. Ly, P.-D., Ly, K.-N., Phan, H.-L., Nguyen, H. H. T., Duong, V.-A., & Nguyen, H. V. (2024). Recent advances in surface decoration of nanoparticles in drug delivery. *Frontiers in Nanotechnology*, *6*. https://doi.org/10.3389/fnano.2024.1456939
3. Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021). Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. *Journal of Personalized Medicine*, *11*(6), 571. https://doi.org/10.3390/jpm11060571

4. Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H. (2019). Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems. *Cancers*, *11*(5), 640. https://doi.org/10.3390/cancers11050640
5. Zhang, M., Liu, C., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025). Advances in cancer immunotherapy: historical perspectives, current developments and future directions. *Molecular Cancer*, *24*(1). https://doi.org/10.1186/s12943-025-02305-x
6. Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2025). MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications. *Journal of Experimental & Clinical Cancer Research*, *44*(1). https://doi.org/10.1186/s13046-025-03391-x
7. Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022). The Promise of Nanotechnology in Personalized Medicine. *Journal of Personalized Medicine*, *12*(5), 673. https://doi.org/10.3390/jpm12050673
8. Fahmy, H. M., Bayoumi, L., Helal, N. F., Mohamed, N. R. A., Emarh, Y., & Ahmed, A. M. (2025). Emerging trends in NanoTheranostics: Integrating imaging and therapy for precision health care. *International Journal of Pharmaceutics*, 126057. https://doi.org/10.1016/j.ijpharm.2025.126057
9. Wang, K., Sun, J., Zhao, H., Wang, F., Zhang, X., Zhao, X., Li, Z., Zhang, L., Ren, H., & Guo, B. (2025). Advances and Challenges in Nano-Delivery Systems for Glioblastoma Treatment: A Comprehensive Review. *International Journal of Nanomedicine*, *Volume 20*, 9597–9620. https://doi.org/10.2147/ijn.s531451
10. Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025). Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products and Regulatory Landscape. *Small*. https://doi.org/10.1002/smll.202502315
11. De Jong, W. H., & Borm, P. J. (2008). Drug delivery and nanoparticles: Applications and hazards. *International Journal of Nanomedicine*, *3*(2), 133. https://doi.org/10.2147/ijn.s596
12. Sharma, S., Parveen, R., & Chatterji, B. P. (2021). Toxicology of Nanoparticles in Drug Delivery. *Current Pathobiology Reports*, *9*(4), 133–144. https://doi.org/10.1007/s40139-021-00227-z
13. Waheed, I., Ali, A., Tabassum, H., Khatoon, N., Lai, W.-F., & Zhou, X. (2024). Lipid-based nanoparticles as drug delivery carriers for cancer therapy. *Frontiers in Oncology*, *14*. https://doi.org/10.3389/fonc.2024.1296091
14. Chehelgerdi, M., Matin Chehelgerdi, Omer Qutaiba Al-lela, Cosme, D., Narayanan Jayasankar, Devendra Pratap Rao, Tamilanban Thamaraikani, Manimaran Vasanthan, Patrik Viktor, Natrayan Lakshmaiya, Saadh, M. J., Amajd, A., Abo-Zaid, M. A., Roxana Yolanda Castillo-Acobo, Ismail, A. H., Amin, A. H., & Reza Akhavan-Sigari. (2023). Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. *Molecular Cancer*, *22*(1). https://doi.org/10.1186/s12943-023-01865-0
15. Shehata, M. M. (2024). ANTICANCER LIPID-BASED DRUG DELIVERY SYSTEMS: BASIC KNOWLEDGE AND RECENT APPLICATIONS. *Nano TransMed*, 100054. https://doi.org/10.1016/j.ntm.2024.100054
16. Zhu, L., Zhou, Z., Mao, H., & Yang, L. (2017). Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and

targeted cancer therapy. *Nanomedicine*, *12*(1), 73–87. https://doi.org/10.2217/nnm-2016-0316
17. Sankaranarayanan, S. A., Thomas, A., Revi, N., Ramakrishna, B., & Rengan, A. K. (2022). Iron oxide nanoparticles for theranostic applications - Recent advances. *Journal of Drug Delivery Science and Technology*, *70*, 103196. https://doi.org/10.1016/j.jddst.2022.103196
18. Karimi, M., Ghasemi, A., Zangabad, P. S., Rahighi, R., Moosavi Basri, S. M., Mirshekari, H., Amiri, M., Pishabad, Z. S., Aslani, A., Bozorgomid, M., Ghosh, D., Beyzavi, A., Vaseghi, A., Aref, A. R., Haghani, L., Bahrami, S., & Hamblin, M. R. (2016). Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. *Chemical Society Reviews*, *45*(5), 1457–1501. https://doi.org/10.1039/c5cs00798d
19. Yang, J., des Rieux, A., & Malfanti, A. (2025). Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases. *ACS Nano*. https://doi.org/10.1021/acsnano.5c00700
20. Pala, R., Anju, V., Dyavaiah, M., Busi, S., & Nauli, S. M. (2020). Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases. *International Journal of Nanomedicine*, *Volume 15*, 3741–3769. https://doi.org/10.2147/ijn.s250872
21. Yang, F., Xue, J., Wang, G., & Diao, Q. (2022). Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. *Frontiers in Pharmacology*, *13*. https://doi.org/10.3389/fphar.2022.999404
22. Chen, Q., Yu, T., Gong, J., & Shan, H. (2025). Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy. *Molecules*, *30*(4), 962. https://doi.org/10.3390/molecules30040962
23. Soumya, R. S., & Raghu, K. G. (2022). Recent advances on nanoparticle-based therapies for cardiovascular diseases. *Journal of Cardiology*, *81*(1). https://doi.org/10.1016/j.jjcc.2022.02.009
24. Asil, S. M., Ahlawat, J., Barroso, G. G., & Narayan, M. (2020). Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. *Biomaterials Science*, *8*(15), 4109–4128. https://doi.org/10.1039/D0BM00809E
25. Asil, S. M., Ahlawat, J., Barroso, G. G., & Narayan, M. (2020). Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. *Biomaterials Science*, *8*(15), 4109–4128. https://doi.org/10.1039/D0BM00809E
26. Rupal Dhariwal, Jain, M., Mir, Y. R., Singh, A., Jain, B., Kumar, P., Tariq, M., Verma, D., Deshmukh, K., Yadav, V. K., & Malik, T. (2025). Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology. *Frontiers in Medicine*, *12*. https://doi.org/10.3389/fmed.2025.1522223
27. Tiwari, P., Prajapati, S. K., Dixit, V., Raza, M. A., Gupta, S. K., & Sharma, M. (2025). Recent advancements in nanoparticle drug delivery systems to cure neurological disorders via the nasal route. *Neurología Argentina*. https://doi.org/10.1016/j.neuarg.2025.05.003
28. World Health Organization. (2024, March 14). *Over 1 in 3 people affected by neurological conditions, the leading cause of illness and disability worldwide*. World Health Organization. https://www.who.int/news/item/14-03-2024-over-1-in-3-people-

affected-by-neurological-conditions--the-leading-cause-of-illness-and-disability-worldwide
29. World Health Organization. (2025). *Cardiovascular Diseases*. World Health Organisation. https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
30. World Health Organization. (2025, February 3). *Cancer*. World Health Organization; World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cancer
31. Ventola, C. L. (2017). Progress in Nanomedicine: Approved and Investigational Nanodrugs. *Pharmacy and Therapeutics*, *42*(12), 742. https://pmc.ncbi.nlm.nih.gov/articles/PMC5720487/
32. Sen, S., Xavier, J., Kumar, N., Ahmad, M. Z., & Ranjan, O. P. (2023). Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. *3 Biotech*, *13*(3). https://doi.org/10.1007/s13205-023-03521-2
33. Hejabi, F., Abbaszadeh, M. S., Taji, S., O'Neill, A., Farjadian, F., & Doroudian, M. (2022). Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems. *Frontiers in Chemistry*, *10*. https://doi.org/10.3389/fchem.2022.957572
34. Joudeh, N., & Linke, D. (2022). Nanoparticle classification, physicochemical properties, characterization and applications: a comprehensive review for biologists. *Journal of Nanobiotechnology*, *20*(1). https://doi.org/10.1186/s12951-022-01477-8
35. Islam, S., Ahmed, M. M. S., Islam, M. A., Hossain, N., & Chowdhury, M. A. (2025). Advances in Nanoparticles in Targeted Drug Delivery- A Review. *Results in Surfaces and Interfaces*, 100529. https://doi.org/10.1016/j.rsurfi.2025.100529